Phase 1 N=20 Roflumilast Plus Antipsychotics Proof of Mechanism Study in Schizophrenia
Schizophrenia
Primary: Change From Baseline in Spatial Span Test Score — -0.199; 0.033; -0.066 score on a scale — p=0.753
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 1 N=109 Pharmacokinetic, Safety, Tolerability and Immunogenicity Study of SB3 in Healthy Male Subjects
Healthy
Primary: Area Under the Concentration-time Curve From Time Zero to Infinity (AUCinf) — 34783.4; 35889.9; 37370.3 µg·h/mL
Phase 1 N=41 Study to Assess the Effect of Rifampicin on Blood Levels and Safety of AZD9291, in Patients With EGFRm+ NSCLC
Non Small Cell Lung Cancer
Primary: Assessment of Maximum Plasma Concentration for AZD9291 After Dosing Alone and in Combination With Rifampicin (Css,Max) — 577.4; 147.5 nanomolar (nM)
Phase 1 N=32 A Study of DKN-01 in Multiple Myeloma or Advanced Solid Tumors
Multiple Myeloma · Solid Tumors · Non-Small Cell Lung Cancer
Primary: Summary of Total Adverse Events (AE) — 39; 58; 35; 11 Events
Phase 1 N=43 Study Of Two Dosing Regimens Of PF-04937319 Compared To An Approved Agent (Sitagliptin) In Patients With Type 2 Diabetes
Type 2 Diabetes Mellitus
Primary: Change From Baseline in Weighted Mean Daily Glucose (WMDG) at Day 14 — -31.24; -31.33; -19.24 milligram/deciliter (mg/dL)
Phase 1 N=80 The Effect of BIA 9-1067 at Steady-state on the Levodopa Pharmacokinetics
Parkinson's Disease (PD)
Primary: Cmax - Maximum Plasma Concentration of Levodopa — 1047; 1203; 1030; 1057 ng/mL
Phase 1 N=27 Pharmacokinetic Single Dose Trial of Empagliflozin in Children and Adolescents With Type 2 Diabetes Mellitus
Diabetes Mellitus, Type 2
Primary: AUC0-inf — 1150; 1430; 5060 nmol*h/L
Phase 1 N=22 A Study to Estimate the Effect of CYP3A4 Inhibitors (Itraconazole, Diltiazem or Verapamil) on the Pharmacokinetics of Single Dose PF- 00489791 in Healthy Volunteers
Healthy Volunteers
Primary: Maximum Observed Plasma Concentration (Cmax) of PF-00489791 — 1140; 1238; 1198; 1186 nanograms per milliliter (ng/mL)
Phase 1 N=43 Safety Study of MM-121 in Combination With Multiple Anticancer Therapies in Patients With Advanced Solid Tumors
Solid Tumors
Primary: To Evaluate the Safety and Tolerability of Escalating Doses of the MM-121 Anticancer Therapies — 3; 8; 5; 3 participants reporting adverse events
Phase 1 N=9 Safety and Pharmacokinetics Study of SyB C-1101 in Patients With Recurrent/Relapsed or Refractory Myelodysplastic Syndrome (MDS)
Myelodysplastic Syndrome
Primary: Adverse Events — 3; 6 participants
Phase 1 N=9 Safety and Pharmacokinetics Study of SyB L-1101 in Patients With Recurrent/Relapsed or Refractory Myelodysplastic Syndrome (MDS)
Myelodysplastic Syndrome
Primary: Number of Participants Who Experienced Dose-limiting Toxicities (DLTs) — 0; 2 participants
Phase 1 N=41 A Study of MM-121 in Combination With Paclitaxel in Patients With Advanced Gynecologic and Breast Cancers
Locally Advanced/Metastatic or Recurrent Ovarian Cancer, Fallopian Tube Cancer, · Primary Peritoneal Cancer or Endometrial Cancer · Locally Advanced/Metastatic Her2 Non Overexpressing Breast Cancer
Primary: Dose Escalation: To Evaluate the Safety and Tolerability of Escalating Doses of the MM-121 Plus Paclitaxel Combination Via Reporting of Dose-limiting Toxicity (DLT) — 0…
Phase 1 N=48 A Safety Study of MM-121 With Cetuximab and Irinotecan in Patients With Advanced Cancers
Colorectal Cancer · Squamous Cell Head and Neck Cancer · Non-small Cell Lung Cancer
Primary: Dose Escalation: To Evaluate the Safety and Tolerability of Escalating Doses of the MM-121 Plus Cetuximab and the MM-121 Plus Cetuximab Plus Irinotecan Combination — 1…
Phase 1 N=64 Study to Determine the Safety, Tolerability and Pharmacokinetics of UV-4B Solution Administered Orally in Healthy Subjects
Viral Infection
Primary: Subjects With Treatment-emergent Adverse Event (TEAEs) by Treatment Group — 5; 6; 5; 5 Subjects with at least 1 TEAE
Phase 1 N=44 Phase I Safety Study of the Drug MM-121 in Patients With Advanced Solid Tumors Resisting Ordinary Treatment
Advanced Solid Tumors
Primary: Objective Response Rate and Duration — 0; 0; 0; 0 participants with objective response